Paclitaxel - CLL PHARMA

Drug Profile

Paclitaxel - CLL PHARMA

Alternative Names: SYN 2001; Syn2001

Latest Information Update: 01 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synt:em
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Brain cancer

Most Recent Events

  • 01 Jun 2016 Chemical structure information added
  • 31 May 2016 Phase-I development is ongoing in Brain cancer in France (CLL PHARMA pipeline, May 2016)
  • 30 May 2013 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top